Print
|
RELATED RESOURCES
SEC Filings:PHAS
PHASEBIO PHARMACEUTICALS INC
3.81
-0.04 (-1.04 %)as of 4:00:00pm ET 03/02/2021
SEC Filings 106–120 of 255
| Year | Type  |
 Date Received |
Period End Date | |
|---|---|---|---|---|
| 2018 | Form 4 | Insider Transaction | 12/17/2018 | 12/13/2018 |
| 2019 | Form SC 13G | Beneficial Ownership Statement | 01/22/2019 | N/A |
| Form SC 13G | Beneficial Ownership Statement | 01/22/2019 | N/A | |
| Form SC 13G | Beneficial Ownership Statement | 01/22/2019 | N/A | |
| Form 8-K* | Current Report* | 01/25/2019 | 01/25/2019 | |
| Form SC 13G/A | Beneficial Ownership Statement | 02/12/2019 | N/A | |
| Form SC 13G/A | Beneficial Ownership Statement | 02/12/2019 | N/A | |
| Form SC 13G/A | Beneficial Ownership Statement | 02/12/2019 | N/A | |
| Form 4 | Insider Transaction | 03/01/2019 | 02/27/2019 | |
| Form 4 | Insider Transaction | 03/01/2019 | 02/28/2019 | |
| Form S-8 POS | Registration statement | 03/01/2019 | N/A | |
| Form S-8 POS | Registration statement | 03/01/2019 | N/A | |
| Form 4 | Insider Transaction | 03/01/2019 | 03/01/2019 | |
| Form 4 | Insider Transaction | 03/01/2019 | 02/27/2019 | |
| Form 4 | Insider Transaction | 03/01/2019 | 02/27/2019 | |
* Financial Reports
Data provided by Vickers Stock Research Corporation, a subsidiary of the Argus Research Group, Inc. All rights reserved.
Performance data shown represents past performance, which is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore, you may have a gain or loss when you sell your shares.
Stock markets are volatile and can decline significantly in response to adverse issuer, political, regulatory, market, or economic developments. Growth stocks can be more volatile than other types of stocks. Value stocks can continue to be undervalued by the market for long periods of time. Foreign securities are subject to interest-rate, currency-exchange-rate, economic, and political risks, all of which are magnified in emerging markets. Illiquidity is an inherent risk associated with investing in real estate and REITs. There is no guarantee the issuer of a REIT will maintain the secondary market for its shares and redemptions may be at a price which is more or less than the original price paid. Closed-end funds can trade at a discount to their NAV. Shareholders of Master Limited Partnerships may be treated as partners for tax purposes. Partnerships issue a Schedule K-1 (Form 1065) rather than a Form 1099 form for tax purposes. It lists the partner's share of income, deductions, credits, etc. Speak with your tax advisor to determine how this may affect you. A royalty trust is a type of corporation, mostly in the United States or Canada, usually involved in oil and gas production or mining. Royalty trusts may have special tax treatment, so you should consult a tax advisor on the potential tax consequences of investing in them.
Any data, charts and other information provided on this page are intended for research purposes to help self-directed investors evaluate many types of securities including, but not limited to common stocks, American Depository Receipts, Master Limited Partnerships, real estate investment trusts. traditional preferred stock, trust preferred securities, third-party trust certificates, convertible securities, mandatory convertible securities and other exchange-traded equity and/or debt securities. Criteria and inputs entered, including the choice to make security comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from its use.
518632.4.0